136 related articles for article (PubMed ID: 35639000)
1. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
[TBL] [Abstract][Full Text] [Related]
2. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
3. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
5. Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab.
Failing JJ; Ho TP; Yadav S; Majithia N; Riaz IB; Shin JY; Schenk EL; Xie H
JCO Oncol Pract; 2020 Jul; 16(7):e573-e580. PubMed ID: 32048920
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis.
Lopez-Olivo MA; Valerio V; Karpes Matusevich AR; Brizio M; Kwok M; Geng Y; Suarez-Almazor ME; Colmegna I
Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016085
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study.
Nakashima K; Homma Y; Taniguchi J; Kubota N; Otsuki A; Ito H; Otsuka Y; Kondo K; Ohfuji S; Fukushima W; Hirota Y
J Infect Chemother; 2023 Nov; 29(11):1038-1045. PubMed ID: 37481070
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
9. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
10. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
[TBL] [Abstract][Full Text] [Related]
11. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
14. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature.
Desage AL; Bouleftour W; Rivoirard R; Magne N; Collard O; Fournel P; Tissot C
Am J Clin Oncol; 2021 Mar; 44(3):109-113. PubMed ID: 33350679
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
16. Influenza vaccines in immunosuppressed adults with cancer.
Eliakim-Raz N; Vinograd I; Zalmanovici Trestioreanu A; Leibovici L; Paul M
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD008983. PubMed ID: 24166741
[TBL] [Abstract][Full Text] [Related]
17. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
18. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
19. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
